Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 984 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vaccine placebo Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers

NCT01542632
View directory record Official record
Conditions
Healthy
Interventions
Takeda's Tetravalent Dengue Vaccine Candidate (TDV), TDV New Formulation, Placebo, New Formulation Placebo
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Fort Collins, Colorado • Galveston, Texas • West Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults

NCT02100631
View directory record Official record
Conditions
Cholera
Interventions
PXVX0200, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
46 Years to 64 Years
Enrollment
398 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
16
States / cities
Mobile, Alabama • DeLand, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults

NCT00831012
View directory record Official record
Conditions
Dengue Fever
Interventions
rDEN3delta30/31-7164
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 15, 2013 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

NCT06695130
View directory record Official record
Conditions
COVID-19 Immunization, Influenza Immunization
Interventions
RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1), RIV + rC19 (dose 2), RIV + rC19 (dose 3), RIV + rC19 (dose 4), Placebo (0.9% NaCl)
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • Cerritos, California • Vista, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age

NCT02186626
View directory record Official record
Conditions
West Nile Virus
Interventions
WN/DEN4Δ30 Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
50 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection

NCT00124215
View directory record Official record
Conditions
Hepatitis C
Interventions
GI-5005
Biological
Lead sponsor
GlobeImmune
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
5
States / cities
Pasadena, California • Denver, Colorado • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2010 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

NCT03275389
View directory record Official record
Conditions
Influenza, Human
Interventions
D-SUIV cH8/1N1+AS03, D-SUIV cH5/1N1+AS03, D-SUIV cH11/1N1+AS03, D-SUIV cH8/1N1+AS01, D-SUIV cH5/1N1+AS01, D-SUIV cH11/1N1+AS01, D-SUIV cH8/1N1, D-SUIV cH5/1N1, D-SUIV cH11/1N1, Placebo, Fluarix Quadrivalent
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 39 Years
Enrollment
470 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
5
States / cities
South Miami, Florida • Wichita, Kansas • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional

Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

NCT00285259
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome
Interventions
VCL-CB01, Phosphate-buffered Saline (PBS)
Biological · Other
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
22
States / cities
Tucson, Arizona • Duarte, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A

NCT01610414
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
23
States / cities
Duarte, California • San Francisco, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults

NCT00301184
View directory record Official record
Conditions
HIV Infections
Interventions
pGA2/JS7 DNA, Modified vaccinia Ankara/HIV62
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial

NCT01011335
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Monovalent rAT, Monovalent rLukS-PV, Bivalent rLukS-PV / rAT, Placebo with adjuvant, Placebo
Biological
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Fort Sam Houston, Texas • Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults

NCT02115815
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Placebo, RSV sF 20 mcg, MEDI7510 (20 mcg RSV sF), RSV sF 50 mcg, MEDI7510 (50 mcg RSV sF), RSV sF 80 mcg, MEDI7510 (80 mcg RSV sF)
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
60 Years to 99 Years
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults

NCT02233816
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine, Placebo
Biological
Lead sponsor
Medicago
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Hollywood, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device

NCT03682107
View directory record Official record
Conditions
Hantavirus Pulmonary Infection, Immunisation
Interventions
Andes virus DNA vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 2, 2026, 2:31 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

NCT03012100
View directory record Official record
Conditions
Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma, Unilateral Breast Carcinoma
Interventions
Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine, Placebo Administration, Sargramostim
Drug · Other · Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
12
States / cities
Scottsdale, Arizona • Duarte, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

NCT05575492
View directory record Official record
Conditions
Cytomegalovirus
Interventions
mRNA-1647, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
9 Years to 25 Years
Enrollment
873 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
44
States / cities
La Mesa, California • Sacramento, California • Fort Collins, Colorado + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety of and Immune Response to the VSV-Indiana HIV Vaccine in Healthy, HIV-Uninfected Adults

NCT01438606
View directory record Official record
Conditions
HIV Infections
Interventions
VSV-Indiana HIV gag vaccine, Placebo injection (normal saline)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
4
States / cities
San Francisco, California • Decatur, Georgia • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds

NCT02114333
View directory record Official record
Conditions
Shingles, Herpes Zoster
Interventions
Zostavax, HZ/su vaccine, Placebo
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation

NCT00633321
View directory record Official record
Conditions
Smoking
Interventions
TA-NIC, Placebo
Biological
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
18 Years and older
Enrollment
522 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
9
States / cities
Sacramento, California • Metairie, Louisiana • Columbia, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults

NCT04966871
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine, PfSPZ Challenge (7G8) for CHMI, Normal Saline
Biological · Other
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

NCT00224484
View directory record Official record
Conditions
Herpes Simplex
Interventions
GSK208141, Havrix (investigational formulation), Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 17 Years · Female only
Enrollment
5,960 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
66
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults

NCT03611946
View directory record Official record
Conditions
Zika Virus
Interventions
Single dose of rZIKV/D4Δ30-713 (10^3 PFU) via subcutaneous injection (0.5ml), Single dose of placebo via subcutaneous injection (0.5ml)., Single dose of rZIKV/D4Δ30-713 (10^4 PFU) via subcutaneous injection (0.5ml)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults

NCT00695877
View directory record Official record
Conditions
HIV Infections
Interventions
Ad5.ENVA.48 HIV-1 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

NCT02685020
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos.HIV, Clade C gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 2, 2026, 2:31 AM EDT